New Data Support The Benefits Of EXPAREL For Postsurgical Analgesia Following Aesthetic Plastic Surgery Procedures
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) have announced results from EXCLAIM, its Phase 4 prospective, observational study to assess the use of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical analgesia in patients undergoing four common plastic surgery procedures. Patients who received EXPAREL following abdominoplasty, breast augmentation, breast reduction or a combination abdominoplasty/breast procedure reported low pain scores, high satisfaction with pain control and minimal opioid use... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 16, 2013 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news
